德展健康(000813.SZ):擬設立科技創新發展中心
格隆匯7月14日丨德展健康(000813.SZ)公佈,公司於2025年7月14日召開第八屆董事會第三十二次會議,審議通過了《關於公司設立科技創新發展中心的議案》。爲了深入整合公司及所屬公司的內外專家資源力量,充分發揮專家團隊科技創新決策外腦支持作用,提升公司科技創新質量,優化科技創新決策機制,公司將設立“科技創新發展中心”。
目前公司與中國工程院楊寶峯院士合作共建的院士工作站已經獲批,需要設立專職機構,依託院士工作站平臺,構建公司科技創新的外腦支持體系,實現科技決策的科學化、專業化和前置化,有效降低創新風險,推動公司科技創新戰略落地。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.